Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis: Aging Clinical and Experimental Research

C. Braschi, S. Capsoni, R. Narducci, A. Poli, G. Sansevero, R. Brandi, L. Maffei, A. Cattaneo, N. Berardi

Research output: Contribution to journalArticlepeer-review


A decrease in brain-derived neurotrophic factor (BDNF), a neurotrophin essential for synaptic function, plasticity and neuronal survival, is evident early in the progression of Alzheimer’s disease (AD), being apparent in subjects with mild cognitive impairment or mild AD, and both proBDNF and mature BDNF levels are positively correlated with cognitive measures. BDNF delivery is, therefore, considered of great interest as a potentially useful therapeutic strategy to contrast AD. Invasive BDNF administration has indeed been recently used in animal models of AD with promising results in rescuing memory deficits, synaptic density and cell loss. Here, we tested whether non-invasive intranasal administration of different BDNF concentrations after the onset of cognitive and anatomical deficits (6 months of age) could rescue neuropathological and memory deficits in AD11 mice, a model of NGF deprivation-induced neurodegeneration. In addition to AD hallmarks, we investigated BDNF effects on microglia presence in the brain of AD11 mice, since alterations in microglia activation have been associated with ageing-related cognitive decline and with the progression of neurodegenerative diseases, including AD. We found that intranasal delivery of 42 pmol BDNF (1 μM), but not PBS, was sufficient to completely rescue performance of AD11 mice both in the object recognition test and in the object context test. No further improvement was obtained with 420 pmol (10 μM) BDNF dose. The strong improvement in memory performance in BDNF-treated mice was not accompanied by an amelioration of AD-like pathology, Aβ burden, tau hyperphosphorylation and cholinergic deficit, but there was a dramatic decrease of CD11b immunoreactive brain microglia. These results reinforce the potential therapeutic uses of BDNF in AD and the non-invasive intranasal route as an effective delivery strategy of BDNF to the brain. They also strengthen the connection between neuroinflammation and neurodegenerative dementia and suggest microglia as a possible mediator of BDNF therapeutic actions in the brain. © 2020, The Author(s).
Original languageEnglish
JournalAging Clin. Exp. Res.
Publication statusPublished - 2020


  • AD11
  • Alzheimer's disease
  • BDNF
  • Neurodegeneration


Dive into the research topics of 'Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis: Aging Clinical and Experimental Research'. Together they form a unique fingerprint.

Cite this